These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 8549297

  • 1. Effect of quinolone use on antimicrobial susceptibility patterns over a 5-year period.
    Segreti J, Connelly R.
    Drugs; 1995; 49 Suppl 2():185-7. PubMed ID: 8549297
    [No Abstract] [Full Text] [Related]

  • 2. The future of the quinolones.
    Andriole VT.
    Drugs; 1999; 58 Suppl 2():1-5. PubMed ID: 10553697
    [Abstract] [Full Text] [Related]

  • 3. Major advances in antibacterial quinolone therapy.
    Neu HC.
    Adv Pharmacol; 1994; 29A():227-62. PubMed ID: 7826861
    [No Abstract] [Full Text] [Related]

  • 4. The antimicrobial activity of sparfloxacin, a new quinolone.
    Paradelis AG, Delidou K, Grigoriadou A, Salpigides G, Pangalis A.
    Drugs; 1995; 49 Suppl 2():238-9. PubMed ID: 8549316
    [No Abstract] [Full Text] [Related]

  • 5. Bacterial resistance to the quinolone antimicrobial agents.
    Hooper DC, Wolfson JS.
    Am J Med; 1989 Dec 29; 87(6C):17S-23S. PubMed ID: 2690616
    [Abstract] [Full Text] [Related]

  • 6. [Susceptibility in vitro to certain quinolines of gram-negative bacteria and gram-positive cocci causing urinary tract infections].
    Mróz E, Jankowski S, Bartelmus J, Grzybek-Hryncewicz K, Ruczkowska J, Starek J, Boratyńska M.
    Med Dosw Mikrobiol; 1993 Dec 29; 45(1):115-8. PubMed ID: 8231429
    [Abstract] [Full Text] [Related]

  • 7. [Results of antimicrobial susceptibilities of strains clinically isolated at 8 institutions in Hiroshima City to major oral antimicrobial drugs, mainly new quinolone drugs. Hiroshima Levofloxacin Susceptibility Surveillance Group].
    Fujiue Y, Kuwabara M, Muroki K, Kohara T, Itaha H, Yamasaki M, Sasaki M, Onimura K, Shigemitsu M, Kashiyama S.
    Jpn J Antibiot; 2000 Jun 29; 53(6):409-21. PubMed ID: 10955237
    [Abstract] [Full Text] [Related]

  • 8. [Quinolones. Gyrase inhibitors].
    Höffler D.
    Internist (Berl); 1994 May 29; 35(5):484-9. PubMed ID: 8021119
    [No Abstract] [Full Text] [Related]

  • 9. In vitro and in vivo antibacterial activities of broad spectrum quinolones against clinical bacterial isolates.
    Matsumoto T, Tateda K, Ishii Y, Ohno A, Miyazaki S, Yamaguchi K.
    Drugs; 1995 May 29; 49 Suppl 2():219-21. PubMed ID: 8549309
    [No Abstract] [Full Text] [Related]

  • 10. Rufloxacin (MF-934): in vitro and in vivo antibacterial activity.
    Ravizzola G, Pinsi G, Pirali F, Colombrita D, Foresti I, Peroni L, Turano A.
    Drugs Exp Clin Res; 1989 May 29; 15(1):11-5. PubMed ID: 2743869
    [Abstract] [Full Text] [Related]

  • 11. [The new quinolones].
    Lontie M.
    J Pharm Belg; 1989 May 29; 44(4):292-301. PubMed ID: 2691640
    [Abstract] [Full Text] [Related]

  • 12. [In vitro evaluation of lomefloxacin].
    Dette GA, Knothe H.
    Arzneimittelforschung; 1989 Aug 29; 39(8):832-5. PubMed ID: 2818672
    [Abstract] [Full Text] [Related]

  • 13. Changing pattern of bacterial susceptibility to antibiotics in hematopoietic stem cell transplant recipients.
    Frère P, Hermanne JP, Debouge MH, Fillet G, Beguin Y.
    Bone Marrow Transplant; 2002 Apr 29; 29(7):589-94. PubMed ID: 11979308
    [Abstract] [Full Text] [Related]

  • 14. Epidemiology of quinolone resistance: Europe and North and South America.
    Goldstein FW, Acar JF.
    Drugs; 1995 Apr 29; 49 Suppl 2():36-42. PubMed ID: 8549361
    [Abstract] [Full Text] [Related]

  • 15. In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.
    Barry AL, Fuchs PC, Brown SD.
    Antimicrob Agents Chemother; 2001 Jun 29; 45(6):1923-7. PubMed ID: 11353655
    [Abstract] [Full Text] [Related]

  • 16. Mechanism of quinolone uptake into bacterial cells.
    Piddock LJ.
    J Antimicrob Chemother; 1991 Apr 29; 27(4):399-403. PubMed ID: 1856120
    [No Abstract] [Full Text] [Related]

  • 17. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2000). I. Susceptibility distribution].
    Kumamoto Y, Tsukamoto T, Fujime M, Fujita K, Hirose T, Matsukawa M, Takahashi S, Kunishima Y, Igari J, Ogihara M, Ishibashi K, Oguri T, Shigeta S, Yamaguchi K, Matsumoto T, Kashitani F, Yoshida H, Imafuku Y, Murai M, Ooe H, Nishikawa M, Watanabe K, Kobayashi Y, Uchida H, Oka T, Kitamura M, Takano Y, Matsuoka Y, Matsuda S, Sato S, Furuhama T, Kumon H, Monden K, Aoki S, Mochida C, Hirakata Y, Kohno S, Miyazaki Y, Tomono K.
    Jpn J Antibiot; 2002 Aug 29; 55(4):370-98. PubMed ID: 12378869
    [Abstract] [Full Text] [Related]

  • 18. Quinolone antimicrobial agents.
    Neu HC.
    Annu Rev Med; 1992 Aug 29; 43():465-86. PubMed ID: 1580602
    [Abstract] [Full Text] [Related]

  • 19. Antimicrobial susceptibility of microorganisms recovered from intraabdominal infections at Belo Horizonte, Brazil.
    dos Santos SG, de Carvalho MA, Serufo JC, Pinto-Silva RA, Albuquerque W, Rosa RV, Pires Ade F, Hahn RC, Hamdan JS, Nicoli JR, Farias Lde M.
    Am J Infect Control; 2004 Nov 29; 32(7):414-6. PubMed ID: 15525917
    [Abstract] [Full Text] [Related]

  • 20. [Studies of lomefloxacin in biliary tract infections].
    Ono Y, Kunii O.
    Jpn J Antibiot; 1989 Apr 29; 42(4):1017-24. PubMed ID: 2769934
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.